About
Developing a bispecific antibody (VEGF/Ang2) targeting wet AMD and diabetic retinal disease, positioned against the incumbent anti-VEGF franchise.
HQ: US
Funding
$330M Series B (2025)
—Company profile
OLN324 — a next-generation VEGF/Ang2 bispecific for retinal disease, backed by the sector's largest 2025 biotech round.
Developing a bispecific antibody (VEGF/Ang2) targeting wet AMD and diabetic retinal disease, positioned against the incumbent anti-VEGF franchise.
HQ: US